ARK Genomic Revolution ETF

ARK Genomic Revolution ETF (ARKG) is ARK Invest's actively managed genomics fund, issued by ARK Investment Management LLC (Cathie Wood's firm) through the ARK ETF Trust. Unlike a passive cap-weighted biotech index, ARKG concentrates in the companies building the measurement-and-read layer of the healthspan stack: sequencing instruments and consumables (Illumina, Pacific Biosciences, 10x Genomics), liquid biopsy and molecular diagnostics (Natera, Guardant, Tempus), CRISPR and genetic-medicine toolmakers (CRISPR Therapeutics, Intellia, Beam, Twist), and computational drug-discovery platforms (Recursion, Schrodinger). Its issuer holdings file maps to a concentrated set of Healthspan companies at weight, making it a thesis-aligned public-fund exposure rather than a broad healthcare sleeve. Note that the single Eli Lilly position is the one demand-beta holding in the file; the rest are tools-and-measurement names consistent with the toll-road thesis the machine applies to this universe. Coverage is limited to direct, issuer-reported positions in already-mapped companies, not the complete portfolio, and this is a research map, not a recommendation. ARKG is most useful for seeing where an active genomics manager concentrates capital across the Measure/Read/Intervene layers. The file's top-two mapped weights sit in 10x Genomics (~8.8%) and Twist Bioscience (~8.7%), anchoring the fund in measurement-and-tools rather than drug development; the single Eli Lilly position is the one demand-beta name.